BridgeBio Pharma, Inc. (BBIO)
67.13
+2.19
(+3.37%)
USD |
NASDAQ |
Oct 15, 16:00
67.13
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Cash from Operations (TTM) : -434.37M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -434.37M |
| March 31, 2026 | -443.95M |
| December 31, 2025 | -445.91M |
| September 30, 2025 | -584.82M |
| June 30, 2025 | -655.81M |
| March 31, 2025 | -500.42M |
| December 31, 2024 | -520.73M |
| September 30, 2024 | -450.22M |
| June 30, 2024 | -414.88M |
| March 31, 2024 | -602.94M |
| December 31, 2023 | -527.72M |
| September 30, 2023 | -495.02M |
| June 30, 2023 | -484.96M |
| March 31, 2023 | -402.06M |
| December 31, 2022 | -419.49M |
| September 30, 2022 | -461.27M |
| Date | Value |
|---|---|
| June 30, 2022 | -447.66M |
| March 31, 2022 | -508.92M |
| December 31, 2021 | -497.93M |
| September 30, 2021 | -460.30M |
| June 30, 2021 | -470.42M |
| March 31, 2021 | -466.56M |
| December 31, 2020 | -399.71M |
| September 30, 2020 | -379.66M |
| June 30, 2020 | -295.47M |
| March 31, 2020 | -277.43M |
| December 31, 2019 | -253.59M |
| September 30, 2019 | -223.80M |
| June 30, 2019 | -214.62M |
| March 31, 2019 | -178.77M |
| December 31, 2018 | -136.64M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Pfizer Inc. | 13.40B |
| Ionis Pharmaceuticals, Inc. | -496.43M |
| BioMarin Pharmaceutical, Inc. | 857.09M |
| Vertex Pharmaceuticals, Inc. | 4.293B |